Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

ZGNX:US

1.5800 USD 0.0200 1.25%

As of 20:10:00 ET on 04/17/2015.

Snapshot for Zogenix Inc (ZGNX)

Open: 1.6100 Day's Range: 1.5800 - 1.6100 Volume: 1,245,593
Previous Close: 1.6000 52wk Range: 1.0700 - 3.1000 1-Yr Rtn: -41.70%

Stock Chart for ZGNX

No chart data available.
  • ZGNX:US 1.5800
  • 1D
  • 1M
  • 1Y
1.6000
Interactive ZGNX Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ZGNX

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.4905
Est. EPS (USD) (12/2015) -0.3700
Est. PEG Ratio -
Market Cap (M USD) 242.31
Shares Outstanding (M) 153.36
30 Day Average Volume 4,272,738
Price/Book (mrq) 4.3835
Price/Sale (ttm) 5.5986
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/08/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ZGNX

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for ZGNX

Zogenix, Inc. is a specialty pharmaceutical company with proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. The Company's products candidates include a product that enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine.

Roger L HawleyCEO/Interim Chief Commercial OfcrStephen J FarrPresident/Co-Founder
Ann D RhoadsExec VP/CFO/Treasurer/SecyBradley Stuart Galer "Brad Gale"Exec VP/Chief Medical Officer
More Company Profile & Key Executives for ZGNX

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil